These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24982037)

  • 1. Difficulties in demonstrating superiority of an antibiotic for multidrug-resistant bacteria in nonrandomized studies.
    Stafford KA; Boutin M; Evans SR; Harris AD
    Clin Infect Dis; 2014 Oct; 59(8):1142-7. PubMed ID: 24982037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering methodological standards for studies of multidrug-resistant bacteria is counterproductive.
    Paul M; Hussein K
    Clin Microbiol Infect; 2016 Jun; 22(6):497-8. PubMed ID: 27050667
    [No Abstract]   [Full Text] [Related]  

  • 3. Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance.
    Rex JH; Talbot GH; Goldberger MJ; Eisenstein BI; Echols RM; Tomayko JF; Dudley MN; Dane A
    Clin Infect Dis; 2017 Jul; 65(1):141-146. PubMed ID: 29017263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination approaches to combat multidrug-resistant bacteria.
    Worthington RJ; Melander C
    Trends Biotechnol; 2013 Mar; 31(3):177-84. PubMed ID: 23333434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late stage antibacterial drugs in the clinical pipeline.
    Projan SJ; Bradford PA
    Curr Opin Microbiol; 2007 Oct; 10(5):441-6. PubMed ID: 17950658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tackling Threats and Future Problems of Multidrug-Resistant Bacteria.
    Medina E; Pieper DH
    Curr Top Microbiol Immunol; 2016; 398():3-33. PubMed ID: 27406189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug combinations: a strategy to extend the life of antibiotics in the 21st century.
    Tyers M; Wright GD
    Nat Rev Microbiol; 2019 Mar; 17(3):141-155. PubMed ID: 30683887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The race for antimicrobials in the multidrug resistance era.
    Molina-Santiago C; de Vicente A; Romero D
    Microb Biotechnol; 2018 Nov; 11(6):976-978. PubMed ID: 29205906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting antibiotic resistance.
    Martínez JL; Baquero F; Andersson DI
    Nat Rev Microbiol; 2007 Dec; 5(12):958-65. PubMed ID: 18007678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multiresistant Bacteria - Antibiotic Prescription and Antibiotics of Last Resort].
    Kern WV
    Dtsch Med Wochenschr; 2018 May; 143(9):643-650. PubMed ID: 29684931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multidrug-resistant bacteria require new treatment options].
    Panknin HT
    Med Monatsschr Pharm; 2015 Dec; 38(12):517-21. PubMed ID: 26837160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Potential of Antibiotics and Nanomaterial Combinations as Therapeutic Strategies in the Management of Multidrug-Resistant Infections: A Review.
    Adeniji OO; Nontongana N; Okoh JC; Okoh AI
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug-resistant organisms and antibiotic management.
    Barie PS
    Surg Clin North Am; 2012 Apr; 92(2):345-91, ix-x. PubMed ID: 22414417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens.
    Infectious Diseases Society of America
    Clin Infect Dis; 2012 Oct; 55(8):1031-46. PubMed ID: 22891041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015.
    Deak D; Outterson K; Powers JH; Kesselheim AS
    Ann Intern Med; 2016 Sep; 165(5):363-72. PubMed ID: 27239977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.
    Schechner V; Temkin E; Harbarth S; Carmeli Y; Schwaber MJ
    Clin Microbiol Rev; 2013 Apr; 26(2):289-307. PubMed ID: 23554418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel antibiotics: are we still in the pre-post-antibiotic era?
    Draenert R; Seybold U; Grützner E; Bogner JR
    Infection; 2015 Apr; 43(2):145-51. PubMed ID: 25701222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far.
    Łusiak-Szelachowska M; Międzybrodzki R; Drulis-Kawa Z; Cater K; Knežević P; Winogradow C; Amaro K; Jończyk-Matysiak E; Weber-Dąbrowska B; Rękas J; Górski A
    J Biomed Sci; 2022 Mar; 29(1):23. PubMed ID: 35354477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Old and new antibiotics for therapy of multidrug resistant bacteria].
    Pintado V
    Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():39-42. PubMed ID: 27608312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey.
    Merli M; Lucidi C; Di Gregorio V; Falcone M; Giannelli V; Lattanzi B; Giusto M; Ceccarelli G; Farcomeni A; Riggio O; Venditti M
    PLoS One; 2015; 10(5):e0127448. PubMed ID: 25996499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.